http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#Head
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#assertion
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#provenance
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#pubinfo
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#assertion
http://purl.obolibrary.org/obo/DOID_2983
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_2983
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00384
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association
http://www.w3.org/2000/01/rdf-schema#label
"Anuria. Severe or progressive kidney disease or dysfunction, with the possible exception of nephrosis. Severe hepatic disease. Hypersensitivity to the drug or any of its components. Triamterene capsules should not be used in patients with pre-existing elevated serum potassium, as is sometimes seen in patients with impaired renal function or azotemia, or in patients who develop hyperkalemia while on the drug. Patients should not be placed on dietary potassium supplements, potassium salts or potassium-containing salt substitutes in conjunction with triamterene capsules. Triamterene capsules should not be given to patients receiving other potassium-sparing agents, such as spironolactone, amiloride hydrochloride, or other formulations containing triamterene. Two deaths have been reported in patients receiving concomitant spironolactone and triamterene capsules or Dyazide (r) Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including triamterene capsules. Hyperkalemia is more likely to occur in patients with renal impairment and diabetes (even without evidence of renal impairment), and in the elderly or severely ill. Since uncorrected hyperkalemia may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients receiving triamterene capsules, when dosages are changed or with any illness that may influence renal function."
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00384
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#provenance
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#pubinfo
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#sig
http://purl.org/nanopub/x/hasSignature
gN1roP4hiJIeLZHnl1xOfuTYh8RqYu6hj+bbrrCb15w3+8Wq7PY+l+ZEmRTy8gOabUnkTIqRwpXp4h6gApCjTJ3aE7lxK3oZ9koY/PscmlCIlbU4YR7ikHjaCgob2H6e3sD22heUJgPPUM5xkSlgSQRd8Hh71SoBrYzaC3NtJtQ=
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M
http://purl.org/dc/terms/created
2021-08-23T18:45:03.617+02:00
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY